How Bael-Basil Tea Can Help Manage Blood Sugar Naturally
Diabetes is no longer just a lifestyle issue - it is a major global health concern. According to the World Health Organisation (WHO), over 422 million people worldwide are living with diabetes, with a large number residing in low and middle-income countries, including India. In fact, India is often referred to as the 'diabetes capital of the world'. A 2023 report by the Indian Council of Medical Research (ICMR) revealed that more than 101 million Indian adults are affected by this condition.
While diabetes cannot be cured, it can be effectively managed through a healthy lifestyle, a balanced diet, and regular monitoring. Alongside conventional treatment, many Indian households turn to natural remedies to support blood sugar control. Two such time-tested herbs are bael and basil (Tulsi), both known for their potent anti-diabetic properties.
Also Read: Diabetes Management: 7 Herbal Teas, For Each Day Of The Week
How Bael Leaves Can Help Manage Diabetes?
Bael, known as 'Bilva' in Sanskrit, is commonly found in Indian households. While the fruit pulp is well-known for digestive health, its leaves have been traditionally used in Ayurveda for managing diabetes.
A study published in the International Journal of Pharmaceutical Sciences highlights that bael leaves contain bioactive compounds like flavonoids and alkaloids, which contribute to their anti-diabetic, antioxidant, and anti-inflammatory effects.
How Basil Leaves Can Help Manage Diabetes?
Tulsi is a staple in Indian kitchens and gardens, revered for its wide range of health benefits. Among its many uses, blood sugar regulation stands out.
A study by Nottingham University found that people with type-2 diabetes who took 250 mg of Tulsi daily, along with their regular medication, experienced significant improvements in blood sugar control. Tulsi's hypoglycaemic properties help lower blood sugar levels and may reduce the risk of diabetes-related complications.
Also Read: Diabetes Diet: How To Make Cinnamon Green Tea To Manage Blood Sugar
Image Credit: iStock
How To Include Bael-Basil Leaves For Diabetes?
While both herbs are effective on their own, using bael and basil together may enhance their benefits. Bael helps stimulate insulin production, while Tulsi improves insulin function and reduces oxidative stress. Together, they offer a holistic approach to managing blood sugar, supporting the pancreas, improving insulin sensitivity, and reducing sugar absorption in the intestines.
Bael-Basil Herbal Tea:
Ingredients:
4-5 bael leaves
5-6 Tulsi leaves
1.5 cups of water
Method:
Boil leaves in water for 10 minutes.
Strain and drink the concoction warm on an empty stomach in the morning.
Word Of Caution: Always consult a healthcare professional before adding herbal remedies to your routine, especially if you're on diabetes medication, to avoid the risk of hypoglycaemia.
Also Read: 5 Easy Daily Diet Routines To Control Diabetes Naturally, Expert Reveals
Bael-Basil Tea: Nature's Powerful Duo for Diabetes:
Nature offers powerful support in managing chronic conditions like diabetes. Bael and basil, deeply rooted in Indian tradition and increasingly backed by modern science, can be valuable additions to your diabetes care regimen. While they are not substitutes for prescribed medication, they may help improve blood sugar control, enhance overall health, and reduce long-term complications.
Disclaimer: This content, including advice, provides generic information only. It is in no way a substitute fora qualified medical opinion. Always consult a specialist or your doctor for more information. NDTV does not claim responsibility for this information.
Advertisement
About Somdatta Saha Explorer- this is what Somdatta likes to call herself. Be it in terms of food, people or places, all she craves for is to know the unknown. A simple aglio olio pasta or daal-chawal and a good movie can make her day.
For the latest food news, health tips and recipes, like us on Facebook or follow us on Twitter and YouTube.
Tags:
Diabetes Management
Bael Leaves Benefits
Tulsi Leaves Benefits
Show full article
Comments
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
40 minutes ago
- India Today
India's Covid tally nears 4,000; Delhi sees highest one-day jump with 47 new cases
The number of active coronavirus cases in India stood at 3,961 on Monday morning, with Delhi reporting the highest single-day increase of 47 new cases, according to the Ministry of Health and Family Welfare. Across the country, 203 new cases were reported one more death linked to Covid-19, taking the total number of fatalities to four, while the total number of infections in the national capital rose to currently the worst-affected state, reported 1,435 active cases, followed by Maharashtra with 506, Delhi with 483, West Bengal with 339, and Gujarat with 338. In addition to Delhi, one Covid-related death each was reported in Kerala, Tamil Nadu, and Maharashtra in the past 24 victim in Delhi was a 22-year-old woman with a pre-existing lung condition, while a 25-year-old man with similar bronchial issues died in Tamil Nadu. Maharashtra reported the death of a 44-year-old man, and details of the fatality in Kerala are to central government sources, the Covid-19 situation in India is being closely monitored by the authorities. The severity of infections remains low, with most patients recovering under home isolation. There is no cause for concern at this time, the sources Monday, Dr Rajiv Bahl, Director General of the Indian Council of Medical Research (ICMR), said that genome sequencing of samples from the western and southern regions of the country has revealed that the variants driving the current surge in cases are subvariants of Omicron and are not associated with severe Omicron subvariants -- LF.7, XFG, JN.1, and NB.1.8.1 -- have been detected, with the first three appearing more frequently, he InMust Watch IN THIS STORY#Covid-19
&w=3840&q=100)
Business Standard
42 minutes ago
- Business Standard
India's Covid cases surge over 15-fold in 10 days: What's behind the spike?
India is witnessing a significant resurgence in Covid-19 cases, with active infections rising from 257 on May 22 to 3,961 by Monday, June 2, a more than 15-fold increase in just ten days, according to the data from the Ministry of Health and Family Welfare (MoHFW). What is driving the sudden surge in Covid-19 cases? Health authorities attribute the rapid increase to the emergence of new, more transmissible Omicron sub-variants, specifically NB.1.8.1 and NF.7, predominantly affecting southern and western India. These variants have led to a rise in cases, especially in densely populated urban areas. Indian Council of Medical Research (ICMR) Director General Dr Rajiv Bahl, mentioned in an interaction with media that the uptick began in southern states, followed by western and now northern regions. The ICMR is closely monitoring the situation through the Integrated Disease Surveillance Programme (IDSP), he said. VIDEO | Delhi: On the recent rise in COVID-19 cases, Indian Council of Medical Research (ICMR) Director General Dr. Rajiv Bahl says, "Cases have been rising, first in southern India, then in western India, and now in northern India. We are monitoring the situation through the… — Press Trust of India (@PTI_News) May 26, 2025 Bahl also said, 'The variants we have sequenced from South and West India are not much severe. 4 variants have been discovered - LF.7 series, XFG series, JN.1 series and NB.1.8.1 series in the same order. We are sequencing the samples from other areas to check for more new variants... The cases are not very severe and people should not worry, but only stay vigilant.' How significant is the increase in Covid-19 cases? The active case count has escalated from 257 on May 22 to 3,961 by June 2, marking an approximate 1,441 per cent increase over ten days. This sharp rise underscores the need for heightened vigilance and adherence to public health measures. What are the govt and health authorities saying? The MoHFW acknowledges the surge but urges the public not to panic, emphasising that most cases are mild. Hospitals have been advised to maintain readiness, ensuring the availability of oxygen, ventilators, and essential medicines. The ICMR continues to monitor the situation and has not issued any new guidelines as of now. However, they stress the importance of vaccination, mask-wearing, and avoiding crowded places to curb the spread. Which states are reporting the highest number of active cases? Kerala remains the most affected state, accounting for a significant portion of the new cases. As of June 2, the states with the highest number of active Covid-19 cases are: Kerala: 1,435 cases Maharashtra: 506 cases Delhi: 483 cases Gujarat: 338 cases West Bengal: 331 cases Karnataka: 253 cases Tamil Nadu: 189 cases Uttar Pradesh: 157 cases What is the severity of the new cases? The majority of new infections present mild symptoms, including sore throat, low-grade fever, congestion, fatigue, and mild gastrointestinal discomfort. Hospitalisations have not seen a significant increase, but the elderly and individuals with pre-existing health conditions are advised to exercise caution. How is Covid-19 detected through testing? 'Standard real-time reverse transcription polymerase chain reaction (RT-PCR) tests are used for diagnosis,' explains Dr Niranjan Patil, AVP at Metropolis Healthcare. 'If a sample tests positive, it is then sent for genomic sequencing to identify the specific variant, such as JN.1.' Main testing options include: RT-PCR (gold standard, accurate but takes 24–48 hours) Rapid Antigen Tests (RATs) (faster but less sensitive) Multiplex PCR tests (such as BioFire, QIAstat) that check for Covid-19 along with other respiratory viruses Test costs: As per government capping, most labs charge between ₹500–₹800 for RT-PCR. Multiplex tests are more expensive. Should you be worried about the resurgence of Covid-19? According to Soumya Swaminathan, former chief scientist of the World Health Organization (WHO) and chairperson of the M S Swaminathan Research Foundation, there is no reason to fear Covid-19 due to the immunity people have acquired over the last few years. She said that the widespread use of vaccines, and in some cases, booster shots, has provided immunity. As a result, even if someone contracts the virus, symptoms will likely be mild, such as a two-day fever, cough, headache, and body aches. VIDEO | On the spike in COVID-19 cases in India, former WHO chief scientist Soumya Swaminathan (@doctorsoumya) says, "Coronavirus will remain with us now in the future too. We will witness a spike in COVID-19 cases in the gap of a few months. However, we have a strong immune… — Press Trust of India (@PTI_News) May 30, 2025 What precautions should the public take? Health authorities recommend the following measures: Continue wearing masks in crowded or enclosed spaces Maintain hand hygiene and physical distancing Ensure vaccinations are up to date, including booster doses Avoid unnecessary travel and large gatherings Seek medical attention if experiencing symptoms consistent with Covid-19 Although the new variants are genetically clever, doctors say they are not necessarily more severe. Still, their ability to evade immunity is what makes them tricky. 'The current variants are not more severe than past variants, but are more transmissible. That's why it's causing concern across Asian countries,' said Dr Sandeep Budhiraja, Group Medical Director – Max Healthcare & Senior Director – Institute of Internal Medicine. Doctors underscore that staying informed through official channels and adhering to public health guidelines without panicking remain crucial in managing the current surge. For more health updates, follow #HealthWithBS
Hindustan Times
an hour ago
- Hindustan Times
Talent loss a major threat to addressing global AMR crisis
Antimicrobial resistance (AMR) is turning out to be one of the major health calamities, with two million deaths projected to occur in India alone by 2025 and 10 million globally. While the discovery of penicillin in 1928, revolutionised the field of medicine and saved millions of lives, the industry has witnessed a constant decline in the development of new antibiotics ever since then. The lack of resources and high investments are the widely considered reasons for this gap, but one key aspect that remains largely overlooked is the loss of potent scientific and research talent for more than two decades. In an in-depth research report, Leaving the Lab, AMR Industry Alliance highlights alarming data on this brain drain phenomenon. According to the study, research and development (R&D) workforce is limited with approximately 3,000 AMR researchers currently active in the world, compared to around 46,000 for cancer and 5,000 for HIV/AIDS. Meanwhile, the total number of authors on all AMR publications declined from a high of 3,599 in 1995 to just 1,827 in 2020. Investigators with a focused research interest in AMR too have further declined since the mid-1990s, falling from a peak of 1,300 to less than 700 by 2020. The situation is even more worrisome in the context of India. According to the World Health Organization (WHO), India contributes only 1% to the global antibacterial R&D pipeline, whereas 84% of this research is concentrated in high-income countries, with another 12% in upper-middle-income economies. For a country like India which not only carries one of the world's highest burdens of AMR but also contributes meaningfully to AMR resistance on the global level, the lack of focus on research and innovation severely undermines the efforts to combat this threat. The 2016 UNGA High-Level Meeting on AMR discussed a number of actions, including talent loss to address these challenges globally. However, the industry is still witnessing slow progress on work to contain AMR. This brain drain could further exacerbate the situation if necessary steps aren't taken to tackle the crisis at hand. This current trajectory of AMR research is deeply troubling and stems from a fundamental market failure. Currently most of the private investors and governments prefer directing fund to research in other disease areas, creating a vacuum for companies and SMEs who actively want to amplify work in the field of AMR. And even if some of the biggest players in the market invest in creating new antibiotics, they often don't attract investment. In recent years, AstraZeneca, Novartis, and Johnson & Johnson have all exited or cut back their work on AMR, including closing R&D facilities, selling antimicrobial portfolios, ending AMR development, and letting go of research teams. While SMEs are more agile and innovative in early-stage research and development of antibiotics in comparison to the bigger players, their situation too is marred by lack of funding globally. According to a report by the BEAM Alliance, 54% of the SME members struggle with enough funds to cover even a year's worth of operations and fear bankruptcy. Biopharmaceutical company, Achaogen is a prime example. Even after securing US FDA approval for plazomicin, the company was still forced to declare bankruptcy in April 2019 – after spending nearly a billion dollars and over a decade developing the antibiotic. This phenomenon further exacerbates the broken market for antimicrobials where major pharmaceutical companies are unable to offer long-term careers as they either fear bankruptcy or lack of investments and funding to continue research. On the incentives front, clinicians in antimicrobial and antifungal R&D teams face significant pay gaps when compared to fellowships across all other specialties. In 2022, 44% of infectious disease fellowships went unfilled in the US – more than double the proportion of unfilled fellowships across all specialties. A 2022 Medscape report showed a pay gap of $4,000 between infectious disease doctors and internal medicine doctors across the US, despite the additional years of training and debt required. While India has made commendable strides in public health in the recent years, AMR continues to represent an unprecedented challenge--it can't be resolved by treatment alone. As the most populated country across the globe, India needs to have a strong, sustained investment in scientific human capital to challenge the future risks related to AMR. The government has initiated varied efforts in identifying and filling gaps in knowledge on the development of new antibiotics and alternatives to existing one to combat AMR. For instance, department of biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC's) mission to amplify research in the identification of new bacterial targets; call for proposals under the AMR Interdisciplinary Research (AMRIT) Team Grants, to foster collaborative research in AMR and collaboration with UK-based innovation charity organisation, Nesta, to create a pipeline of innovators who can develop a point–of–care diagnostic test to conserve antibiotics for future generations, are some of the progressive steps in fight against AMR. Additionally, ICMR's flagship initiative Antimicrobial Resistance Surveillance & Research Network (AMRSN) to generate high-quality data on AMR trends across India through 30 tertiary care hospitals and research institutions; funding R&D in areas such as rapid diagnostics, novel antimicrobials with international bodies like WHO, CDC (USA), and the Fleming Fund are other examples of India's efforts. Despite these efforts, challenges do persist in providing the much-needed boost in generating a talented workforce of scientists, researchers and innovators to fight against AMR. One of the major systemic challenges facing loss of scientific talent is due to academia–industry leakages. Despite producing highly skilled microbiologists, pharmacologists, and biotechnologists, LMICs like India struggle to retain researchers in the AMR domain due to inadequate funding, limited career pathways and lack of translational research ecosystems. Additionally, limited interest from the industry to invest in providing hands-on training to the emerging talent further amplifies the challenges. To mitigate these challenges, India Pharma Inc. needs to support adequate funding and pull incentives to support the talent eager to work in the field of AMR. The industry and the government must come together to support antimicrobial stewardship programs while ensuring adequate resources, and robust research infrastructure to retain and nurture talent in the larger ecosystem. Government bodies like BIRAC should further intensify their schemes like Biotechnology Ignition Grant (BIG) or Small Business Innovation Research Initiative (SBIRI) to seed innovation and support long-term product development, and market access in AMR. Given the alacrity of challenge at hand, India must focus towards creating a robust pipeline or sustained funding ecosystem for retaining talent instrumental in pushing new breakthrough in antibiotic discovery. Ensuring that we have a workforce of trained research personnel will be crucial for research funding to go as far as possible and yield the most successful results to tackle AMR. This article is authored by Saransh Chaudhary, president, Global Critical Care, Venus Remedies Ltd and CEO, Venus Medicine Research Centre.
